Bumetanide nasal spray is bioequivalent to oral bumetanide in 68 healthy adults; Esperion is targeting heart failure care before a 2027 CMS payment model.
|Articles|February 28, 2012
Hospital Opens Personalized Medicine Institute for Cancer and Other Diseases
Advertisement
The Penn State Milton S. Hershey Medical Center and Penn State College of Medicine are opening an institute dedicated to personalized medicine in which clinicians tailor individualized therapies according to patients’ genomic makeups, particularly for oncology patients, to produce better outcomes.
The institute, scheduled to open in June, will collaborate with other departments and institutes at the Hershey campus, including the Penn State Clinical and Translational Science Institute, to advance research in this field and to translate that research into clinical applications.
Read the fully story:
Source: MEDCITY News
Advertisement
Related to this article
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Leukemia survivors given high-risk ALL therapy had hip bone density about 90% of matched controls, without the partial normalization seen in other groups.
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Sacral neuromodulation is still considered the gold standard for refractory overactive bladder, with tibial nerve stimulation a less invasive option.
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
A meta-analysis found teleophthalmology satisfaction comparable to in-person eye care, but showed a gap between recommending it and reusing it.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
3
Sacral Neuromodulation Still Seen as OAB Gold Standard in Review
4
FDA Approves First Symptomatic Dermographism Treatment
5